Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection

Journal of Medical Virology

Volumn 76, Issue 1, 2005, Pages 1-6

  De Mendoza, Carmen ^a   Martín Carbonero, Luz ^a   Gallego, Oscar ^a   Corral, Angélica ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

CD4 lymphocytes; Drug resistance; HIV; Virus replication capacity

Indexed keywords

CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CHRONIC DISEASE; DETERIORATION; DISEASE ASSOCIATION; DISEASE TRANSMISSION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; SEROCONVERSION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MULTIVARIATE ANALYSIS; MUTATION; RNA-DIRECTED DNA POLYMERASE; VIRAL LOAD; VIREMIA;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 15944425696     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20316     Document Type: Article

References (23)

1. Barbour J, Wrin T, Grant R, Martin J, Segal M, Petropoulos C, Deeks S. 2002. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virological failure of protease inhibitor therapy in HIV-infected adults. J Virol 76:11104-11112.
2. Barbour J, Hecht F, Wrin T, Grant R. 2004. Higher CD4 T cell counts associated with low viral pol replication capacity among treatment-naïve adults in early HIV-1 infection, 2004. J Infect Dis 190:251-256.
3. Caliendo A, Savara A, An D, De Vore K, D'Aquila R. 1996. Effects of zidovudine-selected HIV type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J Virol 70:2145-2153.
4. Deeks S, Wrin T, Liegler T, Hoh R, Hayden M, Barbour J, Hellmann N, Petropoulos C, McCune J, Hellerstein M, Grant R. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344:472-480.
5. Deeks S, Hoh R, Grant R, Wrin T, Barbour J, Narvaez A, Cesar D, Abe K, Hanley M, Hellmann N, Petropoulos C, McCune J, Hellerstein M. 2002. CD4+ cell kinetics and activation in HIV-infected patients who remain viremic despite long term treatment with protease inhibitor-based therapy. J Infect Dis 185:315-323.
6. Erickson J, Gulnik S, Markowitz M. 1999. Protease inhibitors: Resistance, cross-resistance, fitness, and the choice of initial and salvage therapies. AIDS 13:189-204.
7. Gallego O, Ruiz L, Vallejo A, Ferrer E, Rubio A, Clotet B, Leal M, Soriano V, ERASE-3 Group. 2001. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS 15:1894-1896.
8. Goudsmit J, de Ronde A, de Rooij E, De Boer R. 1997. Broad spectrum of in vivo fitness of HIV type 1 sub-populations differing at reverse transcriptase codons 41 and 215. J Virol 71:4479-4484.
9. Grant R, Hecht F, Warmerdam M, Liu L, Lieger T, Petropoulos C, Hellmann N, Chesney M, Busch M, Hahn J. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288:181-188.
10. Kaufmann D, Pantaleo G, Sudre P, Telenti A. 1998. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 351:723-724.
11. Larder B, Kemp S, Harrigan R. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
12. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francoli P, Weber R. 1999. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet 353:863-868.
13. Martinez-Picado J, Savara A, Sutton L, D'Aquila R. 1999. Replicative fitness of protease inhibitor-resistant mutants of HIV type 1. J Virol 73:3744-3752.
14. Miller M, White K, Petropoulos C, Parkin N. 2003. Decreased replication capacity of HIV-1 clinical isolates containing K65R or M184V RT mutations [abstract 616]. 10th Conference on Retroviruses and Opportunistic Infections. Boston 10-14, February 2003. USA.
15. Nijhuis M, Schuurman R, De Jong D, Erickson J, Gustchina E, Schipper J, Gulnik S, Boucher C. 1999. Increased fitness of drug resistant HIV-1 protease as result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
16. Nijhuis M, Deeks S, Boucher C. 2001. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 14:23-28.
17. Pazhanisamy S, Stuver C, Cullinan A, Margolin N, Rao B, Livingston D. 1996. Kinetic characterization of HIV type 1 protease-resistant variants. J Biol Chem 271:17979-17985.
18. Renaud M, Katlama C, Mallet A, Calvez V, Carcelain G, Tubiana R, Jouan M, Caumes E, Agut H, Bricaire F, Debre P, Autran B. 1999. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 13: 669-676.
19. Sharma P, Crumpacker C. 1999. Decreased processivity of HIV type 1 reverse transcriptase (RT) containing didanosine-selected mutation L74V: A comparative analysis of RT variants L74V and lamivudine-selected M184V. J Virol 73:8448-8456.
20. Sloand E, Kumar P, Kim S, Chaudhuri A, Weichold F, Young N. 1999. HIV type 1 protease inhibitor modulates activation of peripheral blood CD4+ T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 94:1021-1027.
21. Stürmer M, Staszewski S, Doerr H, Larder B, Bloor S, Hertogs K. 2003. Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of HIV type 1: Interpretation of established mutations and characterization of new polymorphism at codons 208, 211, and 214. J Virol 47:54-61.
22. White K, Margot N, Wrin T, Petropoulos C, Miller M, Naeger L. 2002. Molecular mechanisms of resistance to HIV type 1 with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chem 46:3437-3446.
23. Yeni P, Hammer S, Carpenter C, Cooper D, Fischl M, Gatell J, Gazzard B, Hirsch M, Jacobsen D, Katzenstein D, Montaner J, Richman D, Saag M, Schechter M, Schooley R, Thompson M, Vella S, Volberding P. 2002. Antiretroviral treatment for adult HIV infection in 2002: Update recommendations of the International AIDS Society-USA Panel. JAMA 288:222-235.